Mark Daly, Ph.D. (MGH/Broad, Analytical and Translational Genetics Unit) has more than twenty years’ collaborative experience in mapping human disease genes, including scientific leadership of the HapMap and 1000 Genomes projects to detect standing genetic variation in human populations; development of platforms and methods to perform genome-wide association studies in case/control and population-based cohorts; and discovery of over 150 validated risk loci in psychiatric diseases (autism, bipolar, attention deficit hyperactivity disorder, schizophrenia), autoimmune/inflammatory diseases (Crohn’s disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus), and metabolic diseases (type 2 diabetes, obesity). His lab today is specifically focused two major areas – extending insights gained from the many genes discovered to pursue the functional and clinical ramifications thereof and of extending their analytic expertise to thorough processing and analysis of next-generation sequencing in order to apply it to psychiatric diseases as well as rare Mendelian diseases.